MYCN and neuroblastoma: Increased expression of AURKA, independent of MYCN amplification, is a negative prognostic factor in neuroblastoma, and AURKA inhibition with alisertib has shown efficacy in pre-clinical cell line xenograft models [16, 17] as well as activity and safety in a pediatric Phase I trial in combination with chemotherapy [18].